Haemonetics Launches TEG 6s PlateletMapping Assay Cartridge
Zacks Investment Research | Nov 21, 2019 05:48AM ET
Haemonetics Corporation (NYSE:HAE) recently initiated commercial roll out of its four-channel TEG 6s PlateletMapping ADP (NASDAQ:ADP) & AA assay cartridge globally. Designed to be used with the TEG 6s Hemostasis Analyzer System, the cartridge has already attained the FDA approval in the United States for use in cardiology and cardiovascular surgery. The cartridge has also attained the CE mark and is commercially available in overseas markets with broader indications.
The global commercial availability of the cartridge is expected to bolster Haemonetics’ TEG portfolio.
More About the TEG 6s PlateletMapping Cartridge
The PlateletMapping ADP & AA cartridge is used by clinicians to evaluate a patient’s bleeding and thrombotic risk, which can happen as a consequence of inhibition of platelet function. The assay provides four channels of dried-in-place reagents including HKH (Kaolin with Heparinase), ActF (Activator F), ADP (adenosine-5'-diphosphate) and AA (Arachidonic Acid), enabling clinicians to assess a patient's coagulation ability.
The PlateletMapping ADP & AA cartridge provides clinicians swift and accurate results that are required to study a patient's platelet function. With this information, doctors can easily determine the necessary diagnosis and treatment.
For investors’ notice, the TEG 6s PlateletMapping assay is the only cartridge-based hemostasis analyzer that aids a clinician to study both global hemostasis and platelet function at the site of care.
Market Prospects
Per Grand View Research , the global clot management market was worth $1.26 billion in 2015 and is anticipated to reach a value of $1.88 billion by 2024, growing at a CAGR of 4.6%.
Recent Development
In May 2019, Haemonetics attained 510(k) clearance from the FDA to broaden the medical application of its TEG 6s Hemostasis Analyzer System for use in adult trauma settings. This regulatory go-ahead comes on account of the current use for the TEG 6s system in cardiovascular surgery and cardiology procedures, making it the first-ever cartridge-based system available in the United States to study the hemostasis condition in adult trauma patients.
Price Performance
In a year’s time, shares of Haemonetics have gained 17.5% compared with the industry ’s 8.2% growth.
Get The News You Want
Stocks Worth a Look
Haemonetics has a Zacks Rank #2 (Buy).Some other top-ranked stocks from the broader medical space are CONMED (NASDAQ:CNMD) , NuVasive, Inc. (NASDAQ:NUVA) and ResMed (NYSE:RMD) , each carrying a Zacks Rank #2. You can see
CONMED has a projected long-term earnings growth rate of 17%.
NuVasive has an expected long-term earnings growth rate of 10.9%.
ResMed has a long-term earnings growth rate of 12.9%.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.